JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) had its target price upped by research analysts at JPMorgan Chase & Co. from $165.00 to $167.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 31.19% from the company’s current price.

Several other equities research analysts have also commented on the stock. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Wedbush reissued an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, TD Cowen dropped their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $191.57.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $127.30 on Wednesday. The stock’s 50 day moving average price is $133.61 and its 200 day moving average price is $132.99. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The company has a market cap of $7.73 billion, a PE ratio of -15.75 and a beta of 0.65.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Blue Trust Inc. raised its position in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares during the last quarter. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $60,000. GAMMA Investing LLC lifted its stake in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Signaturefd LLC boosted its position in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.